Interpace Biosciences Expects Third-Quarter 2026 Revenue of $10.1M–$10.4M
Interpace Biosciences said preliminary, unaudited revenue for the quarter ended September 30, 2026 is expected to range from $10.1 million to $10.4 million.
Related stories
Asian Stocks Slide as Tech Selloff Intensifies
Asian stock markets declined on Friday, mirroring losses on Wall Street as technology and artificial intelligence shares came under renewed selling pressure following disappointing
H impact | EARNINGS | Oct 30, 2026, 01:26 AM UTC
NEXTDC Cuts Annual Forecasts; Shares Slip
NEXTDC shares fell after the Australian company slashed its annual forecasts.
M impact | EARNINGS | Oct 30, 2026, 01:26 AM UTC
Aboitiz Equity Ventures Posts Consolidated Net Income of 17.8 Billion Pesos
M impact | EARNINGS | Oct 30, 2026, 01:25 AM UTC
South Korean Shares Extend Losses on AI Concerns
The benchmark KOSPI edged down 0.09% to around 1,337 on Friday, extending losses for a second session as AI-related concerns weighed on investor sentiment. The sell-off followed ov
L impact | EARNINGS | Oct 30, 2026, 01:19 AM UTC
Amazon cash burn and Intel’s weak PC demand highlight AI costs
Results from Amazon and Intel heightened concerns about the costs of the AI infrastructure race and its effects on technology and consumers.
M impact | EARNINGS | Oct 30, 2026, 01:16 AM UTC
OMG Group Reports Q1 FY27 Net Sales of A$1.92M
M impact | EARNINGS | Oct 30, 2026, 01:07 AM UTC